- Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
- Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
- Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
- Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
More ▼
Key statistics
On Friday, Arvinas Inc (ARVN:NSQ) closed at 24.83, 82.98% above the 52 week low of 13.57 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.85 |
---|---|
High | 25.12 |
Low | 23.39 |
Bid | 23.50 |
Offer | 26.67 |
Previous close | 23.90 |
Average volume | 1.18m |
---|---|
Shares outstanding | 68.43m |
Free float | 62.30m |
P/E (TTM) | -- |
Market cap | 1.64bn USD |
EPS (TTM) | -6.05 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼